Following a previous positive opinion from EFSA (European Food Safety Agency), GALLIPRO® Fit probiotic has now been approved for sale in the EU by the European Commission. GALLIPRO® Fit was first successfully launched in the US in 2017, followed by Australia in 2018 and the South African and Asian markets in 2019.
“We are really excited to get this approval after research data and field trials have documented the efficacy and safety of GALLIPRO® Fit. We see it as an official blue stamp of our probiotic solution for some of the poultry industry’s biggest challenges that customers in other parts of the world have benefitted from since 2017,” says Dorthe Sandvang, DVM, PhD, from Chr. Hansen’s Animal Health Innovation.
“GALLIPRO® Fit is the trademark for Chr. Hansen’s first probiotic to combine three unique strains in one product to address some of the key challenges faced by poultry producers today. Together, the three novel strains in GALLIPRO® Fit have been proven to effectively support the digestive performance and a healthy normal immune system in broilers, pullet layers/breeders and turkeys. At the same time, it brings production profitability,” she elaborates.
Success around the world
With the registration and regulatory approval secured in Europe, Chr. Hansen is now able to bring the successful product to a new region – and is also preparing for a launch in a new EMEA markets in 2021.
“Over the past years we have witnessed a very positive adoption of GALLIPRO® Fit by customers in the US, Australia, Asia and South Africa. We can’t wait to bring this highly relevant solution to European and other EMEA markets,” says Christophe Bostvironnois, senior global product manager for Poultry at Chr. Hansen.
GALLIPRO® Fit has been proven to be effective in the following key areas:
- Boosts husbandry management by supporting normal physiological functions
- Contributes to food safety
- Risk reduction of failure with specific laboratory assays
With feed representing 68% of the cost of broiler production1, production profitability is important, and margins are under pressure.
Protecting poultry from Clostridium perfringens, Salmonella and Escherichia coli is key for farmers to get the highest productivity for their chickens. In 2019, 1 in 3 outbreaks of foodborne disease was due to Salmonella. Poland, Spain and Slovakia reported the highest rate of Salmonella outbreaks that year.2 Also, uncontrolled clostridiosis in production systems can cost more than 0.05 €/ bird.3
GALLIPRO® Fit contains unique strains of bacteria that are selected for their relative effectiveness at demonstrating beneficial modes of action, making them particularly suitable for improving the success of commercial poultry operations.
“From our library of bacterial strains, we carefully select strains with a research-proven ability to influence animal welfare, support a normal immune system and keep birds healthier. With GALLIPRO® Fit we are bringing a tried and tested solution to help European poultry farmers protect their business,” concludes Bostvironnois.
1 Wageningen UR 2014
3 Poultry world 2018
GALLIPRO® Fit is a trademark of Chr. Hansen A/S
科 汉森是一家全球性且具备差异化的生物科技公司，为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森，我们拥有独特的优势，可通过微生物解决方案推动积极的变革。 在过去超过 145 年的时间里，我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力，库存广泛且价值重大，包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外，我们还将挖掘释放有益菌的力量，以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司，我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动，公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。